Downregulating STAT6 in a clinical setting may, therefore, combine the effects of many of these drugs, making it an attractive target for drug development to treat severe, uncontrolled T2 high asthma.
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Hosted on MSN3mon
Kymera's IND Application for STAT6 Degrader Gets FDA ClearanceSTAT6 is a historically undrugged essential transcription factor in the IL-4/IL-13 signaling pathways and the central driver of T helper type 2 (TH2) inflammation in allergic diseases. Sanofi SNY ...
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could presage further deals in STAT6, where ...
We found that interleukin 4 receptor (IL-4R) knockout and downstream signal transducer and activator of transcription 6 (STAT6) knockout, but not IL-4 knockout, mice resisted tumor recurrence ...
Under terms of the deal, Johnson & Johnson will gain an exclusive license to the STAT6 program, with Kaken maintaining commercialization rights in Japan. Johnson & Johnson (J&J) announced that it has ...
Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback